论文部分内容阅读
目的 探讨瘤体内直接注射途径的 p1 6抑癌基因疗法与粒细胞 巨噬细胞集落刺激因子 (GM CSF)基因疗法联合应用对小鼠肾癌 (renca)的治疗效果及其免疫学机理。方法 建立皮下荷瘤肾癌小鼠模型 ,于接种肿瘤细胞 3d后将荷瘤小鼠随机分为 5组 ,分别给予不同的治疗 ,检测每组小鼠的免疫功能 ,观察每组小鼠的存活期 ,并行肿瘤病理学分析。结果 Adp1 6+AdGM CSF联合治疗组小鼠有 2只长期存活 (存活时间 >90d) ,其他 4组荷瘤小鼠均在 52d内死亡。联合治疗组小鼠与其他 4组相比 ,存活期明显延长 ,差异有非常显著性 (P <0 .0 1 )。联合治疗组小鼠自然杀伤细胞(NK)杀伤率为 33% ,与其他 4组相比 ,差异有非常显著性 (P <0 .0 1 )。结论 p1 6与GM CSF联合基因疗法的应用可增强小鼠抗肿瘤免疫反应 ,并抑制肿瘤生长 ,延长荷瘤小鼠的存活期
Objective To investigate the therapeutic effect and immunological mechanism of p16 tumor suppressor gene therapy combined with granulocyte-macrophage colony-stimulating factor (GM CSF) gene therapy in mouse renal carcinoma (renca). Methods A subcutaneous tumor-bearing mouse model of renal cell carcinoma was established. Tumor-bearing mice were randomly divided into 5 groups after inoculation of tumor cells for 3 days, and the mice were given different treatments. The immune function of each group was tested and the survival of mice in each group was observed Period, parallel tumor pathology analysis. Results Two of the mice in Adp1 6 + AdGM CSF group had long-term survival (survival time> 90 days), and the other four groups had died within 52 days. Compared with other 4 groups, the mice in the combined treatment group showed significantly longer survival, the difference was significant (P <0.01). The killing rate of natural killer cells (NK) in the combination therapy group was 33%, which was significantly different from the other 4 groups (P <0.01). Conclusion The combination of p16 and GM CSF gene therapy can enhance anti-tumor immune response, inhibit tumor growth and prolong the survival of tumor-bearing mice